Dag Nyholm

List of Publications by Year
in descending order

118 papers	4,847 citations	109321 35 h-index	102487 66 g-index
123 all docs	123 docs citations	123 times ranked	3347 citing authors

#	Article	IF	Citations
1	Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. Brain, 2023, 146, 1065-1074.	7.6	18
2	Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus. Journal of Neuroimaging, 2022, 32, 90-96.	2.0	9
3	Optimizing Treatment of Parkinson's Disease. Journal of Personalized Medicine, 2022, 12, 245.	2.5	0
4	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2022, 19, 15.	5.0	7
5	Composite attenuation correction method using a 68Ge-transmission multi-atlas for quantitative brain PET/MR. Physica Medica, 2022, 97, 36-43.	0.7	3
6	The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study. Journal of Neuropathology and Experimental Neurology, 2022, 81, 545-552.	1.7	11
7	Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System. JMIR Formative Research, 2022, 6, e31485.	1.4	2
8	Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211080.	3.5	28
9	Effects of Helicobacter pylori on Levodopa Pharmacokinetics. Journal of Parkinson's Disease, 2021, 11, 61-69.	2.8	20
10	Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease. Movement Disorders, 2021, 36, 481-491.	3.9	12
11	Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice. Journal of Personalized Medicine, 2021, 11, 254.	2.5	33
12	Close relationships in Parkinson´s disease patients with device‐aided therapy. Brain and Behavior, 2021, 11, e02102.	2.2	5
13	Personalized Medicine Approach in Treating Parkinson's Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice. Journal of Personalized Medicine, 2021, 11, 720.	2.5	6
14	Imaging features associated with idiopathic normal pressure hydrocephalus have high specificity even when comparing with vascular dementia and atypical parkinsonism. Fluids and Barriers of the CNS, 2021, 18, 35.	5.0	18
15	An updated calculator for determining levodopa-equivalent dose. Neurological Research and Practice, 2021, 3, 58.	2.0	16
16	Pain, disease severity and associations with individual quality of life in patients with motor neuron diseases. BMC Palliative Care, 2021, 20, 154.	1.8	2
17	Motion Sensor-Based Assessment of Parkinson's Disease Motor Symptoms During Leg Agility Tests: Results From Levodopa Challenge. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 111-119.	6.3	14
18	Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinson's Disease. Occupational Therapy in Health Care, 2020, 34, 1-18.	0.3	0

#	Article	IF	Citations
19	A multiple motion sensors index for motor state quantification in Parkinson's disease. Computer Methods and Programs in Biomedicine, 2020, 189, 105309.	4.7	12
20	A survey of lifestyle factors in dystonia. Brain and Behavior, 2020, 10, e01871.	2.2	1
21	Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data. Journal of Parkinson's Disease, 2020, 10, 1529-1534.	2.8	6
22	Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. Scientific Reports, 2020, 10, 18057.	3.3	17
23	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Movement Disorders, 2020, 35, 606-615.	3.9	25
24	A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Movement Disorders, 2020, 35, 1046-1054.	3.9	12
25	Accuracy and precision of zero-echo-time, single- and multi-atlas attenuation correction for dynamic [11C]PE2I PET-MR brain imaging. EJNMMI Physics, 2020, 7, 77.	2.7	7
26	How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. Journal of Neurology, 2019, 266, 3038-3046.	3.6	21
27	Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience. Journal of Neurology, 2019, 266, 651-658.	3.6	15
28	Evaluation of a sensor algorithm for motor state rating in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 112-117.	2.2	2
29	Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects. Scientific Reports, 2019, 9, 4129.	3.3	30
30	The effect of continuous levodopa treatment during the afternoon hours. Acta Neurologica Scandinavica, 2019, 139, 70-75.	2.1	10
31	Unsupervised Learning from Motion Sensor Data to Assess the Condition of Patients with Parkinson's Disease. Lecture Notes in Computer Science, 2019, , 420-424.	1.3	0
32	Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. CNS Neuroscience and Therapeutics, 2018, 24, 439-447.	3.9	20
33	A Treatment-Response Index From Wearable Sensors for Quantifying Parkinson's Disease Motor States. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 1341-1349.	6.3	40
34	Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. Acta Neurologica Scandinavica, 2018, 138, 78-84.	2.1	5
35	Individual dose-response models for levodopa infusion dose optimization. International Journal of Medical Informatics, 2018, 112, 137-142.	3.3	9
36	A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. Movement Disorders, 2018, 33, 329-332.	3.9	14

#	Article	IF	Citations
37	Evaluation of zero-echo-time attenuation correction for integrated PET/MR brain imagingâ€"comparison to head atlas and 68Ge-transmission-based attenuation correction. EJNMMI Physics, 2018, 5, 20.	2.7	19
38	Safety and tolerability of IRL790 in Parkinsonâ€™s disease with levodopa-induced dyskinesiaâ€"a phase 1b trial. Npj Parkinson's Disease, 2018, 4, 35.	5.3	14
39	Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinsonâ€™s disease patients. European Journal of Clinical Pharmacology, 2018, 74, 1299-1307.	1.9	13
40	Levodopa/carbidopa microtablets in Parkinsonâ€™s disease: a study of pharmacokinetics and blinded motor assessment. European Journal of Clinical Pharmacology, 2017, 73, 563-571.	1.9	40
41	Feasibility of spirography features for objective assessment of motor function in Parkinson's disease. Artificial Intelligence in Medicine, 2017, 81, 54-62.	6.5	15
42	Development of new levodopa treatment strategies in Parkinsonâ€™s diseaseâ€"from bedside to bench to bedside. Upsala Journal of Medical Sciences, 2017, 122, 71-77.	0.9	19
43	First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 727-731.	2.1	10
44	Levodopa-carbidopa enteral suspension in advanced Parkinsonâ€™s disease: clinical evidence and experience. Therapeutic Advances in Neurological Disorders, 2017, 10, 171-187.	3.5	21
45	Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study. Movement Disorders, 2017, 32, 283-286.	3.9	70
46	A smartphone-based system to quantify dexterity in Parkinson's disease patients. Informatics in Medicine Unlocked, 2017, 9, 11-17.	3.4	40
47	Using measurements from wearable sensors for automatic scoring of Parkinson's disease motor states: Results from 7 patients. , 2017, 2017, 131-134.		6
48	Verification of a Method for Measuring Parkinsonâ€™s Disease Related Temporal Irregularity in Spiral Drawings. Sensors, 2017, 17, 2341.	3.8	16
49	Initiation of Levodopa-Carbidopa IntestinalÂGel Infusion Using Telemedicine (Video Communication) Tj ETQq1 1 0.784314 rgBT /Over Disease. Journal of Parkinson's Disease, 2017, 7, 719-728.	2.8	29
50	Development of a clinically feasible [C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 263-274.	1.0	5
51	Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease. Acta Neurologica Scandinavica, 2016, 133, 208-215.	2.1	11
52	Levodopaâ€"Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Review. CNS Drugs, 2016, 30, 381-404.	5.9	81
53	Authorsâ€™ Reply to Lambarth: â€œLevodopa-Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Reviewâ€. CNS Drugs, 2016, 30, 1009-1010.	5.9	1
54	Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsonâ€™s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism and Related Disorders, 2016, 29, 17-23.	2.2	43

#	ARTICLE	IF	CITATIONS
55	Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e95.	2.2	0
56	A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1. Clinical Neuropharmacology, 2015, 38, 170-176.	0.7	20
57	Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson's Disease. Sensors, 2015, 15, 23727-23744.	3.8	51
58	Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1829-1834.	6.3	13
59	Use of ^{11}C-PE2I PET in Differential Diagnosis of Parkinsonian Disorders. Journal of Nuclear Medicine, 2015, 56, 234-242.	5.0	41
60	Feasibility of Spirography Features for Objective Assessment of Motor Symptoms in Parkinson's Disease. Lecture Notes in Computer Science, 2015, , 267-276.	1.3	0
61	A computer vision framework for finger-tapping evaluation in Parkinson's disease. Artificial Intelligence in Medicine, 2014, 60, 27-40.	6.5	53
62	Levodopa Fractionation in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 89-96.	2.8	14
63	Continuous Drug Delivery in Parkinson's Disease. CNS Drugs, 2014, 28, 19-27.	5.9	40
64	Visualization of Spiral Drawing Data of Patients with Parkinson's Disease. , 2014, , .		3
65	Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurologica Scandinavica, 2013, 127, 124-132.	2.1	24
66	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
67	Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients. AAPS Journal, 2013, 15, 316-323.	4.4	83
68	Motor fluctuations and Helicobacter pylori in Parkinson's disease. Journal of Neurology, 2013, 260, 2974-2980.	3.6	40
69	Spiral drawing during self-rated dyskinesia is more impaired than during self-rated off. Parkinsonism and Related Disorders, 2013, 19, 553-556.	2.2	4
70	Validation of parametric methods for [11C]PE2I positron emission tomography. NeuroImage, 2013, 74, 172-178.	4.2	10
71	Automatic and Objective Assessment of Alternating Tapping Performance in Parkinson's Disease. Sensors, 2013, 13, 16965-16984.	3.8	36
72	Stochastic anomaly detection in eye-tracking data for quantification of motor symptoms in Parkinson's disease. AIP Conference Proceedings, 2013, , .	0.4	4

#	ARTICLE	IF	CITATIONS
73	Computer Vision Methods for Parkinsonian Gait Analysis: A Review on Patents. Recent Patents on Biomedical Engineering, 2013, 6, 97-108.	0.5	8
74	Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations. Recent Patents on Biomedical Engineering, 2013, 6, 127-135.	0.5	0
75	Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 6-14.	0.7	25
76	Pharmacokinetics of Levodopa/Carbidopa Microtablets Versus Levodopa/Benserazide and Levodopa/Carbidopa in Healthy Volunteers. Clinical Neuropharmacology, 2012, 35, 111-117.	0.7	35
77	Clinical Experience of Dose Conversion Ratios Between 2 Botulinum Toxin Products in the Treatment of Cervical Dystonia. Clinical Neuropharmacology, 2012, 35, 278-282.	0.7	16
78	Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. Parkinsonism and Related Disorders, 2012, 18, 686-687.	2.2	4
79	Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa–carbidopa intestinal gel in the absence of head-to-head comparisons. Basal Ganglia, 2012, 2, 221-226.	0.3	3
80	Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 1000-1001.	2.2	20
81	Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety. Parkinsonism and Related Disorders, 2012, 18, 916-929.	2.2	68
82	Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. Neurological Sciences, 2012, 33, 831-838.	1.9	13
83	Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurologica Scandinavica, 2012, 126, e29-e33.	2.1	54
84	Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. European Journal of Neurology, 2012, 19, 820-826.	3.3	39
85	Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. European Journal of Neurology, 2012, 19, 1079-1085.	3.3	75
86	A Pharmacokinetic-Pharmacodynamic Model for Duodenal Levodopa Infusion. Clinical Neuropharmacology, 2011, 34, 61-65.	0.7	30
87	A web application for follow-up of results from a mobile device test battery for Parkinson's disease patients. Computer Methods and Programs in Biomedicine, 2011, 104, 219-226.	4.7	22
88	Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Annals of Neurology, 2011, 69, 424-424.	5.3	10
89	Long-term Efficacy and Safety with Continuous Dopaminergic Stimulation Pump Treatments in Parkinson's Disease. European Neurological Review, 2011, 6, 156.	0.5	2
90	Circadian Rhythmicity in Levodopa Pharmacokinetics in Patients With Parkinson Disease. Clinical Neuropharmacology, 2010, 33, 181-185.	0.7	24

#	Article	IF	Citations
91	A home environment test battery for status assessment in patients with advanced Parkinson's disease. Computer Methods and Programs in Biomedicine, 2010, 98, 27-35.	4.7	49
92	A new computer method for assessing drawing impairment in Parkinson's disease. Journal of Neuroscience Methods, 2010, 190, 143-148.	2.5	68
93	Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. European Journal of Neurology, 2010, 17, 260-266.	3.3	33
94	Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurologica Scandinavica, 2010, 121, 237-243.	2.1	44
95	Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurologica Scandinavica, 2009, 119, 345-348.	2.1	39
96	Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden. Applied Health Economics and Health Policy, 2009, 7, 167-180.	2.1	21
97	P1.175 Deflning a test score for status assessment during motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S74.	2.2	0
98	Soft Tissue-anchored Transcutaneous Port Attached to an Intestinal Tube for Long-term Gastroduodenal Infusion of Levodopa/Carbidopa in Parkinson Disease. Journal of Vascular and Interventional Radiology, 2009, 20, 500-505.	0.5	17
99	Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurologica Scandinavica, 2008, 118, 379-386.	2.1	51
100	Novel administration routes for levodopa and dopamine agonists. European Journal of Pharmaceutical Sciences, 2008, 34, S13-S14.	4.0	0
101	Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 193-203.	3.3	92
102	Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 63-73.	0.7	108
103	The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S13-S17.	2.2	47
104	Irreversible motor impairment in young addicts ? ephedrone, manganism or both?. Acta Neurologica Scandinavica, 2007, 115, 385-389.	2.1	1,023
105	Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease. Clinical Pharmacokinetics, 2006, 45, 109-136.	3.5	139
106	Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 509-513.	2.2	13
107	Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements. Neurology, 2006, 66, 1611-1612.	1.1	18
108	Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Review of Neurotherapeutics, 2006, 6, 1403-1411.	2.8	72

#	Article	IF	Citations
109	Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology, 2005, 64, 216-223.	1.1	407
110	Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements:. Neurology, 2005, 65, 1506-1507.	1.1	56
111	Wireless real–time electronic data capture for self–assessment of motor function and quality of life in Parkinson's disease. Movement Disorders, 2004, 19, 446-451.	3.9	57
112	Levodopa Infusion Therapy in Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 245-256.	0.7	58
113	New developments in levodopa therapy. Neurology, 2004, 62, S9-16.	1.1	33
114	An automatic dose dispenser for microtablets—a new concept for individual dosage of drugs in tablet form. International Journal of Pharmaceutics, 2003, 261, 137-146.	5.2	42
115	Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets. Clinical Neuropharmacology, 2003, 26, 156-163.	0.7	206
116	Levodopa Pharmacokinetics and Motor Performance During Activities of Daily Living in Patients With Parkinson's Disease on Individual Drug Combinations. Clinical Neuropharmacology, 2002, 25, 89-96.	0.7	78
117	Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurologica Scandinavica, 2001, 104, 343-348.	2.1	150
118	Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology, 0, , 10.1212/WNL.0000000000200804.	1.1	9